 | • レポートコード：MRC2208A0028 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、160ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、世界の子宮頸がん診断検査市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、診断検査別（パップスメア検査、HPV検査、コルポスコピー、生検＆子宮頸管内掻爬術、その他）分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、Abbott、BD、Cooper Companies, Inc.、DYSIS Medical, Inc.、F. Hoffmann-La Roche Ltd.、Femasys, Inc.、Guided Therapeutics, Inc.、Hologic, Inc.、QIAGEN、Quest Diagnostics Incorporatedなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の子宮頸がん診断検査市場規模：診断検査別（パップスメア検査、HPV検査、コルポスコピー、生検＆子宮頸管内掻爬術、その他） ・世界の子宮頸がん診断検査市場規模：エンドユーザー別 ・世界の子宮頸がん診断検査市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Cervical Cancer Diagnostic Tests Market – Scope of Report
TMR’s report on the global cervical cancer diagnostic tests market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global cervical cancer diagnostic tests market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cervical cancer diagnostic tests market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cervical cancer diagnostic tests market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cervical cancer diagnostic tests market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global cervical cancer diagnostic tests market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cervical cancer diagnostic tests market.
The report delves into the competitive landscape of the global cervical cancer diagnostic tests market. Key players operating in the global cervical cancer diagnostic tests market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cervical cancer diagnostic tests market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market cervical cancer diagnostic tests.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cervical Cancer Diagnostic Tests Market
4. Market Overview
4.1. Introduction
4.1.1. Diagnostic Test Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, by Diagnostic Test
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Diagnostic Test, 2017–2031
6.3.1. Pap Smear Test
6.3.2. HPV Test
6.3.3. Colposcopy
6.3.4. Biopsy & Endocervical Curettage
6.3.5. Other diagnostic tests
6.4. Market Attractiveness Analysis, by Diagnostic Test
7. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Cervical Cancer Diagnostic Tests Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Cervical Cancer Diagnostic Tests Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Diagnostic Test, 2017–2031
9.2.1. Pap Smear Test
9.2.2. HPV Test
9.2.3. Colposcopy
9.2.4. Biopsy & Endocervical Curettage
9.2.5. Other diagnostic tests
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Diagnostic Test
9.5.2. By End-user
9.5.3. By Country
10. Europe Cervical Cancer Diagnostic Tests Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnostic Test, 2017–2031
10.2.1. Pap Smear Test
10.2.2. HPV Test
10.2.3. Colposcopy
10.2.4. Biopsy & Endocervical Curettage
10.2.5. Other diagnostic tests
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Diagnostic Test
10.5.2. By End-user
10.5.3. By Country Country/Sub-region
11. Asia Pacific Cervical Cancer Diagnostic Tests Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnostic Test, 2017–2031
11.2.1. Pap Smear Test
11.2.2. HPV Test
11.2.3. Colposcopy
11.2.4. Biopsy & Endocervical Curettage
11.2.5. Other diagnostic tests
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Others
11.4. Market Value Forecast, by Country Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Diagnostic Test
11.5.2. By End-user
11.5.3. By Country Country/Sub-region
12. Latin America Cervical Cancer Diagnostic Tests Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnostic Test, 2017–2031
12.2.1. Pap Smear Test
12.2.2. HPV Test
12.2.3. Colposcopy
12.2.4. Biopsy & Endocervical Curettage
12.2.5. Other diagnostic tests
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Hospitals
12.3.2. Specialty Clinics
12.3.3. Others
12.4. Market Value Forecast, by Country Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Diagnostic Test
12.5.2. By End-user
12.5.3. By Country Country/Sub-region
13. Middle East & Africa Cervical Cancer Diagnostic Tests Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnostic Test, 2017–2031
13.2.1. Pap Smear Test
13.2.2. HPV Test
13.2.3. Colposcopy
13.2.4. Biopsy & Endocervical Curettage
13.2.5. Other diagnostic tests
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Hospitals
13.3.2. Specialty Clinics
13.3.3. Others
13.4. Market Value Forecast, by Country Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Diagnostic Test
13.5.2. By End-user
13.5.3. By Country Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Abbott
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. BD
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Cooper Companies, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. DYSIS Medical, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. F. Hoffmann-La Roche Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Femasys, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Guided Therapeutics, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Hologic, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. QIAGEN
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.10. Quest Diagnostics Incorporated
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
Table 01: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, by Product, 2022–2031
Table 02: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, by End-user, 2022–2031
Table 03: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn) Forecast, by Region, 2022–2031
Table 04: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country, 2022–2031
Table 05: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022–2031
Table 06: North America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022–2031
Table 07: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 08: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022–2031
Table 09: Europe Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022–2031
Table 10: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 11: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022–2031
Table 12: Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022–2031
Table 13: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 14: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022–2031
Table 15: Latin America Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022–2031
Table 16: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 17: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by Product, 2022–2031
Table 18: Middle East & Africa Cervical Cancer Diagnostic Tests Market Revenue (US$ Mn) Forecast, by End-user, 2022–2031